Skip to main content
MedPathMedPath Home
Clinical Trials/JPRN-jRCT2080222787
JPRN-jRCT2080222787
Unknown
Phase 3

Confirmatory Study for AD-810N in Patients with Parkinsonism in Dementia with Lewy Bodies.(Phase 3 study)

Sumitomo Dainippon Pharma Co., Ltd.0 sites300 target enrollmentStarted: March 9, 2015Last updated:
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit

Overview

Phase
Phase 3
Enrollment
300
OverviewEligibility CriteriaInvestigatorsRecords & IdentifiersSimilar Trials

Overview

Brief Summary

No summary available.

Study Design

Study Type
Interventional

Eligibility Criteria

Ages
>= 20age old to <= 89age old (—)
Sex
All

Inclusion Criteria

  • •Patients met the diagnostic criteria of probable DLB
  • •\- Outpatients
  • •\- Patients taking L\-DOPA/DCI in succession more than 12 weeks

Exclusion Criteria

  • •\- Patients with parkinsonism excepting Dementia with Lewy Bodies
  • •\- Patients with Parkinson's disease with dementia
  • •\- Epileptic patients
  • •\- Patients treated with zonisamide

Investigators

Similar Trials

Unknown
Phase 2
An Exploratory Study for AD-810N in Patients with Parkinsonism in Dementia with Lewy Bodies (Phase 2 study)
JPRN-jRCT2080221994Dainippon Sumitomo Pharma Co., Ltd.150
Unknown
Phase 3
A double-blind confirmatory study for AD-810N (zonisamide) in patients with Parkinson's disease (Phase III)Parkinson's disease
JPRN-jRCT2080221162Dainippon Sumitomo Pharma Co., Ltd.360
Active, not recruiting
Phase 1
A Phase 1 trial of pf-03084014 in patients with advanced solid tumor malignancy and t-cell acute lymphoblastic leukemia/lymphoblastic lymphoma - NDadvanced solid tumor malignancies or relapsed or refractory acute T-cell lymphoblastic leukemia/lymphoblastic lymphoma (T-ALL/LBL).MedDRA version: 9.1Level: LLTClassification code 10066110MedDRA version: 9.1Level: LLTClassification code 10065252MedDRA version: 9.1Level: LLTClassification code 10065923
EUCTR2010-022036-36-ITPfizer Inc., 235 East 42nd Street, New York, NY 1001760
Terminated
Phase 2
Cemdisiran and eculizumab dose-ranging study for paroxysmal nocturnal haemoglobinuriaParoxysmal nocturnal haemoglobinuria (PNH)Haematological DisordersParoxysmal nocturnal haemoglobinuria [Marchiafava-Micheli]
ISRCTN31882639niversity of Leeds9
Active, not recruiting
Phase 1
A study that continues from APD334-003 which investigates the safety and effectiveness of treatment with the drug APD334 in patients with ulcerative colitis (a form of inflammatory bowel disease)
EUCTR2015-002109-12-BGArena Pharmaceuticals, Inc.118